Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

被引：54
|
作者：
Palomba, Maria Lia
Gordon, Leo I.
Siddiqi, Tanya
Abramson, Jeremy S.
Kamdar, Manali
Lunning, Matthew A.
Maloney, David G.
Andreadis, Charalambos
Arnason, Jon E.
Ghosh, Nilanjan
Mehta, Amitkumar
Solomon, Scott R.
Farazi, Thalia
Garcia, Jacob
Dehner, Christine
Ogasawara, Ken
Gao, Jie
Wang, Michael
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136158
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
    Abramson, Jeremy S.
    Siddiqi, Tanya
    Gordon, Leo, I
    Lunning, Matthew Alexander
    Wang, Michael
    Arnason, Jon E.
    Mehta, Amitkumar N.
    Purev, Enkhee
    Maloney, David G.
    Andreadis, Charalambos
    Sehgal, Alison R.
    Solomon, Scott R.
    Ghosh, Nilanjan
    Albertson, Tina M.
    Garcia, Jacob
    Kostic, Ana
    Li, Daniel
    Kim, Yeonhee
    Palomba, Maria Lia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Efficacy and safety of zanubrutinib in patients with relapsed or refractory mantle cell lymphoma: a systematic review
    Santoso, A. Febrian
    Margouw, R. Relia
    Maulidia, S. Azrianindita
    Kurniawan, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1341 - S1341
  • [33] Impact of lisocabtagene maraleucel (liso-cel) treatment on health-related quality of life and health utility in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: TRANSCEND NHL 001 (NCT02631044)
    Patrick, D.
    Powers, A.
    Jun, M. Parisi
    Kim, Y.
    Garcia, J.
    Dehner, C.
    Maloney, D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 220 - 221
  • [34] TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as SecondLine Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma
    Morschhauser, Franck
    Dahiya, Saurabh
    Palomba, M. Lia
    Garcia-Sancho, Alejandro Martin
    Reguera, Juan Luis
    Kuruvilla, John
    Jaeger, Ulrich
    Cartron, Guillaume
    Izutsu, Koji
    Dreyling, Martin
    Kahl, Brad S.
    Ghesquieres, Herve
    Ardeshna, Kirit
    Goto, Hideki
    Barbui, Anna Maria
    Abramson, Jeremy S.
    Borchmann, Peter
    Fleury, Isabelle
    Mielke, Stephan
    Skarbnik, Alan
    de Vos, Sven
    Kamdar, Manali
    Karmali, Reem
    Viardot, Andreas
    Farazi, Thalia
    Fasan, Omotayo
    Lymp, James
    Vedal, Min
    Nishii, Rina
    Avilion, Ariel
    Papuga, Jessica
    Nastoupil, Loretta J.
    BLOOD, 2023, 142
  • [35] Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
    Abramson, Jeremy S.
    Gordon, Leo I.
    Palomba, Maria Lia
    Lunning, Matthew Alexander
    Arnason, Jon E.
    Forero-Torres, Andres
    Wang, Michael
    Maloney, David G.
    Sehgal, Alison
    Andreadis, Charalambos
    Purev, Enkhtsetseg
    Solomon, Scott R.
    Ghosh, Nilanjan
    Albertson, Tina M.
    Xie, Benhuai
    Garcia, Jacob
    Siddiqi, Tanya
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] TRANSCEND CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel in Combination With Ibrutinib for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 18 - 19
  • [37] Updated Safety and Long-Term Clinical Outcomes in TRANSCEND NHL 001, Pivotal Trial of Lisocabtagene Maraleucel (JCAR017) in R/R Aggressive NHL
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 9 - 11
  • [38] TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Palomba, M. Lia
    Garcia, Jacob
    Wang, Lei
    Dehner, Christine
    Chung, Karen C.
    Maloney, David G.
    BLOOD, 2018, 132
  • [39] Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Kim, Austin I.
    Armand, Philippe
    Redd, Robert A.
    Forsyth, Megan
    Branch, Paul
    Pazienza, Samantha
    Brennan, Lisa
    Patterson, Victoria
    Waisgerber, Susan M.
    Merryman, Reid W.
    Fisher, David C.
    Ryan, Christine E.
    Ahn, Inhye E.
    Crombie, Jennifer L.
    Odejide, Oreofe O.
    LaCasce, Ann
    Jacobson, Caron A.
    Jacobsen, Eric
    Parry, Erin M.
    Davids, Matthew S.
    Brown, Jennifer R.
    Freedman, Arnold S.
    Riedell, Peter A.
    Murakami, Mark Alan
    BLOOD, 2023, 142
  • [40] Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma
    Patrick, Donald L.
    Powers, Annette
    Jun, Monika Parisi
    Kim, Yeonhee
    Garcia, Jacob
    Dehner, Christine
    Maloney, David G.
    BLOOD ADVANCES, 2021, 5 (08) : 2245 - 2255
12345